Rosiglitazone does not improve vascular function in subjects with chronic kidney disease

Thiazolidinedione Drugs and Cardiovascular Risks

(2010) Sanjay Kaul et al.   CIRCULATION

Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration

(2010) Janet Woodcock et al.   NEW ENGLAND JOURNAL OF MEDICINE

The emerging pleiotrophic role of adipokines in the uremic phenotype

(2009) Juan Jesús Carrero et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients

(2009) S. P.B. Ramirez et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

(2009) Steven M. Brunelli et al.   KIDNEY INTERNATIONAL

The Relationship Between Nontraditional Risk Factors and Outcomes in Individuals With Stage 3 to 4 CKD

(2008) Daniel E. Weiner et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Media Calcification and Intima Calcification Are Distinct Entities in Chronic Kidney Disease

(2008) K. Amann   Clinical Journal of the American Society of Nephrology

Dissociation between the Insulin-Sensitizing Effect of Rosiglitazone and Its Effect on Hepatic and Intestinal Lipoprotein Production

(2008) Hélène Duez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α–Dependent Manner In Vitro and In Vivo in Mice

(2008) Gabriela Orasanu et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease

(2007) C. A. Schneider et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY